NCT05736029 Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics
| NCT ID | NCT05736029 |
| Status | Recruiting |
| Phase | — |
| Sponsor | OncoHost Ltd. |
| Condition | Non Small Cell Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 350 participants |
| Start Date | 2022-11-07 |
| Primary Completion | 2028-01-01 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The goal of this exploratory study is understand the mechanisms of response to immunotherapy in Non-Small Cell Lung Cancer patients. The investigators are going to search for correlation between specific biological features and response to immunotherapy, and to use those associations for developing an algorithm enabling to identify patients that could benefit from the immune check inhibitor based anti cancer treatment. Patients will provide biological samples before and during their treatment, and clinical data will be collected.
Eligibility Criteria
Inclusion Criteria: * Provision of informed consent prior to any study-specific procedures. * Male or female aged at least 18 years. * ECOG PS - 0/1-2. Exclusion Criteria: * Any concurrent and/or other active malignancy that has required systemic treatment within 2 years of first dose of treatment. * Generalized impairment or mental incompetence that would render the patient unable to understand his/her participation in the study.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.